EpiTyping: analysis of epigenetic aberrations in parental imprinting and X-chromosome inactivation using RNA-seq

Nissim Benvenisty, Roni Sarel-Gallily, Gal Keshet, Shay Kinreich, Guy Haim-Abadi

Published: 2023-10-31 DOI: 10.1038/s41596-023-00898-5

RNA Sequencing

Human Pluripotent Stem Cells

Epigenetic Aberrations

Parental Imprinting

X-Chromosome Inactivation

AI 解读

Deoxyfluorination of phenols for chemoselective18F-labeling of peptides

Stable isotope tracing to assess tumor metabolism in vivo

Measuring DNA modifications with the comet assay: a compendium of protocols

Detect-seq, a chemical labeling and biotin pull-down approach for the unbiased and genome-wide off-target evaluation of programmable cytosine base editors

A systems-level mass spectrometry-based technique for accurate and sensitive quantification of the RNA cap epitranscriptome

Spooling electrochemiluminescence spectroscopy: development, applications and beyond

Chronic, cortex-wide imaging of specific cell populations during behavior

Chromatin accessibility profiling by ATAC-seq

Global analysis of RNA-binding protein dynamics by comparative and enhanced RNA interactome capture

Pooled genetic perturbation screens with image-based phenotypes

查看全部

Sections

Figures

References

De Los Angeles, A. et al. Hallmarks of pluripotency. Nature 525, 469–478 (2015).
Shahbazi, M. N., Siggia, E. D. & Zernicka-Goetz, M. Self-organization of stem cells into embryos: a window on early mammalian development. Science 364, 948–951 (2019).
Avior, Y., Sagi, I. & Benvenisty, N. Pluripotent stem cells in disease modelling and drug discovery. Nat. Rev. Mol. Cell Biol. 17, 170–182 (2016).
Trounson, A. & DeWitt, N. D. Pluripotent stem cells progressing to the clinic. Nat. Rev. Mol. Cell Biol. 17, 194–200 (2016).
Halliwell, J., Barbaric, I. & Andrews, P. W. Acquired genetic changes in human pluripotent stem cells: origins and consequences. Nat. Rev. Mol. Cell Biol. 21, 715–728 (2020).
Avior, Y., Lezmi, E., Eggan, K. & Benvenisty, N. Cancer-related mutations identified in primed human pluripotent stem cells. Cell Stem Cell 28, 10–11 (2021).
Lezmi, E. & Benvenisty, N. Identification of cancer-related mutations in human pluripotent stem cells using RNA-seq analysis. Nat. Protoc. 16, 4522–4537 (2021).
Ben-David, U., Mayshar, Y. & Benvenisty, N. Virtual karyotyping of pluripotent stem cells on the basis of their global gene expression profiles. Nat. Protoc. 8, 989–997 (2013).
Bar, S. & Benvenisty, N. Epigenetic aberrations in human pluripotent stem cells. EMBO J. 38, e101033 (2019).
Weinberger, L., Ayyash, M., Novershtern, N. & Hanna, J. H. Dynamic stem cell states: naive to primed pluripotency in rodents and humans. Nat. Rev. Mol. Cell Biol. 17, 155–169 (2016).
Yilmaz, A. & Benvenisty, N. Defining human pluripotency. Cell Stem Cell 25, 9–22 (2019).
Reik, W. & Walter, J. Genomic imprinting: parental influence on the genome. Nat. Rev. Genet. 2, 21–32 (2001).
Tucci, V. et al. Genomic imprinting and physiological processes in mammals. Cell 176, 952–965 (2019).
Bar, S., Schachter, M., Eldar-Geva, T. & Benvenisty, N. Large-scale analysis of loss of imprinting in human pluripotent stem cells. Cell Rep. 19, 957–968 (2017).
Keshet, G. & Benvenisty, N. Large-scale analysis of imprinting in naive human pluripotent stem cells reveals recurrent aberrations and a potential link to FGF signaling. Stem Cell Rep. 16, 2520–2533 (2021).
Nora, E. P. & Heard, E. X chromosome inactivation: when dosage counts. Cell 139, 865–867 (2009).
Brown, C. J. et al. The human XIST gene: analysis of a 17 kb inactive X-specific RNA that contains conserved repeats and is highly localized within the nucleus. Cell 71, 527–542 (1992).
Heard, E. & Disteche, C. M. Dosage compensation in mammals: fine-tuning the expression of the X chromosome. Genes Dev. 20, 1848–1867 (2006).
Shen, Y. et al. X-inactivation in female human embryonic stem cells is in a nonrandom pattern and prone to epigenetic alterations. Proc. Natl Acad. Sci. USA 105, 4709–4714 (2008).
Bruck, T. & Benvenisty, N. Meta-analysis of the heterogeneity of X chromosome inactivation in human pluripotent stem cells. Stem Cell Res. 6, 187–193 (2011).
Patel, S. et al. Human embryonic stem cells do not change their X inactivation status during differentiation. Cell Rep. 18, 54–67 (2017).
Yokobayashi, S. et al. Inherent genomic properties underlie the epigenomic heterogeneity of human induced pluripotent stem cells. Cell Rep. 37, 109909 (2021).
Bar, S., Seaton, L. R., Weissbein, U., Eldar-Geva, T. & Benvenisty, N. Global characterization of X chromosome inactivation in human pluripotent stem cells. Cell Rep. 27, e3 (2019).
Werner, J. M., Ballouz, S., Hover, J. & Gillis, J. Variability of cross-tissue X-chromosome inactivation characterizes timing of human embryonic lineage specification events. Dev. Cell 57, 1995–2008.e5 (2022).
Theunissen, T. W. et al. Molecular criteria for defining the naive human pluripotent state. Cell Stem Cell 19, 502–515 (2016).
Sagi, I. & Benvenisty, N. Aspiring to naivety. Nature 540, 211–212 (2016).
Sarel-Gallily, R. & Benvenisty, N. Large-scale analysis of X inactivation variations between primed and naïve human embryonic stem cells. Cells 11, 1729 (2022).
Sherry, S. T. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29, 308–311 (2001).
Morison, I. M., Ramsay, J. P. & Spencer, H. G. A census of mammalian imprinting. Trends Genet. 21, 457–465 (2005).
Carrel, L. & Willard, H. F. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature 434, 400–404 (2005).
Tukiainen, T. et al. Landscape of X chromosome inactivation across human tissues. Nature 550, 244–248 (2017).
Surani, M. A. H., Barton, S. C. & Norris, M. L. Development of reconstituted mouse eggs suggests imprinting of the genome during gametogenesis. Nature 308, 548–550 (1984).
McGrath, J. & Solter, D. Completion of mouse embryogenesis requires both the maternal and paternal genomes. Cell 37, 179–183 (1984).
Sagi, I. et al. Distinct imprinting signatures and biased differentiation of human androgenetic and parthenogenetic embryonic stem cells. Cell Stem Cell 25, 419–432.e9 (2019).
Cassidy, S. B., Schwartz, S., Miller, J. L. & Driscoll, D. J. Prader–Willi syndrome. Genet. Med. 14, 10–26 (2012).
Margolis, S. S., Sell, G. L., Zbinden, M. A. & Bird, L. M. Angelman syndrome. Neurotherapeutics 12, 641–650 (2015).
Weksberg, R., Shuman, C. & Beckwith, J. B. Beckwith–Wiedemann syndrome. Eur. J. Hum. Genet. 18, 8–14 (2010).
Ishida, M. New developments in Silver–Russell syndrome and implications for clinical practice. Epigenomics 8, 563–580 (2016).
Foong, Y. H., Thorvaldsen, J. L. & Bartolomei, M. S. Two sides of the Dlk1-Dio3 story in imprinting. Dev. Cell 56, 3035–3037 (2021).
Jinnah, H. A. Lesch–Nyhan disease: from mechanism to model and back again. Dis. Model. Mech. 2, 116–121 (2009).
Hoffman, E. P., Brown, R. H. & Kunkel, L. M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919–928 (1987).
Migeon, B. R. X-linked diseases: susceptible females. Genet. Med. 22, 1156–1174 (2020).
Mekhoubad, S. et al. Erosion of dosage compensation impacts human iPSC disease modeling. Cell Stem Cell 10, 595–609 (2012).
Eisen, B. et al. Electrophysiological abnormalities in induced pluripotent stem cell‐derived cardiomyocytes generated from Duchenne muscular dystrophy patients. J. Cell. Mol. Med. 23, 2125 (2019).
Da Cruz, L. et al. Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration. Nat. Biotechnol. 36, 328–337 (2018).
Sonntag, K. C. et al. Pluripotent stem cell-based therapy for Parkinson’s disease: current status and future prospects. Prog. Neurobiol. 168, 1–20 (2018).
Chen, S., Du, K. & Zou, C. Current progress in stem cell therapy for type 1 diabetes mellitus. Stem Cell Res. Ther. 11, 275 (2020).
Lozano-Ureña, A. et al. Aberrations of genomic imprinting in glioblastoma formation. Front. Oncol. 11, 630482 (2021).
Fu, J. et al. DNA methylation of imprinted genes KCNQ1, KCNQ1OT1, and PHLDA2 in peripheral blood is associated with the risk of breast cancer. Cancers 14, 2652 (2022).
Zhou, J. et al. Epigenetic imprinting alterations as effective diagnostic biomarkers for early-stage lung cancer and small pulmonary nodules. Clin. Epigenetics 13, 220 (2021).
Lim, D. H. K. & Maher, E. R. Genomic imprinting syndromes and cancer. Adv. Genet. 70, 145–175 (2010).
Davies, H. D. et al. Myeloid leukemia in Prader–Willi syndrome. J. Pediatr. 142, 174–178 (2003).
Wang, D. et al. Abnormal X chromosome inactivation and tumor development. Cell. Mol. Life Sci. 77, 2949–2958 (2020).
Spatz, A., Borg, C. & Feunteun, J. X-chromosome genetics and human cancer. Nat. Rev. Cancer 4, 617–629 (2004).
Silva, S. S., Rowntree, R. K., Mekhoubad, S. & Lee, J. T. X-chromosome inactivation and epigenetic fluidity in human embryonic stem cells. Proc. Natl Acad. Sci. USA 105, 4820–4825 (2008).
Bock, C. et al. Quantitative comparison of genome-wide DNA methylation mapping technologies. Nat. Biotechnol. 28, 1106–1114 (2010).
Yong, W. S., Hsu, F. M. & Chen, P. Y. Profiling genome-wide DNA methylation. Epigenetics Chromatin 9, 26 (2016).
Irizarry, R. A. et al. Comprehensive high-throughput arrays for relative methylation (CHARM). Genome Res. 18, 780–790 (2008).
Taiwo, O. et al. Methylome analysis using MeDIP-seq with low DNA concentrations. Nat. Protoc. 7, 617–636 (2012).
Brinkman, A. B. et al. Whole-genome DNA methylation profiling using MethylCap-seq. Methods 52, 232–236 (2010).
Meissner, A. et al. Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res. 33, 5868–5877 (2005).
Li, Q., Hermanson, P. J. & Springer, N. M. Detection of DNA methylation by whole-genome bisulfite sequencing. Methods Mol. Biol. 1676, 185–196 (2018).
Kluin, R. J. C. et al. XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data. BMC Bioinforma. 19, 366 (2018).
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120 (2014).
Brouard, J. S., Schenkel, F., Marete, A. & Bissonnette, N. The GATK joint genotyping workflow is appropriate for calling variants in RNA-seq experiments. J. Anim. Sci. Biotechnol. 10, 1–6 (2019).
Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
Danecek, P. & McCarthy, S. A. BCFtools/csq: haplotype-aware variant consequences. Bioinformatics 33, 2037–2039 (2017).
Li, H. Tabix: fast retrieval of sequence features from generic TAB-delimited files. Bioinformatics 27, 718 (2011).
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).
Frankish, A. et al. GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res. 47, D766–D773 (2019).
Hu, Z. et al. Transient inhibition of mTOR in human pluripotent stem cells enables robust formation of mouse-human chimeric embryos. Sci. Adv. 6, eaaz0298 (2020).

EpiTyping: analysis of epigenetic aberrations in parental imprinting and X-chromosome inactivation using RNA-seq

Supplementary information

推荐阅读